Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sally Watkins

Nurse Practitioner, Acute Care Columbus, GA Nurse Practitioner

NPI 1437634011 CMS profile 10537559

2121 Warm Springs Rd, Columbus, GA 31904

Open in the dashboard

General payments

$7,689

353 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sally Watkins of Columbus, GA is reported in the CMS Open Payments database as having received $7,689 across 353 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,996 44
2024 General $1,037 44
2023 General $1,254 72
2022 General $1,746 93
2021 General $1,656 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sally Watkins
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Sally Watkins were reported at $1,996. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Sally Watkins Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,656 $123 $38–$327 $132
2022 $1,746 $130 $44–$369 $149
2023 $1,254 $144 $49–$410 $160
2024 $1,037 $146 $48–$433 $164
2025 $1,996 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,825 16 payments
  2. Novartis Pharmaceuticals Corporation $802 51 payments
  3. Abbott Laboratories $738 19 payments
  4. Pfizer Inc. $567 46 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $448 29 payments
  6. E.R. Squibb & Sons, L.L.C. $422 33 payments
  7. Novo Nordisk Inc $358 21 payments
  8. Janssen Pharmaceuticals, Inc $339 30 payments
  9. Esperion Therapeutics, Inc. $305 13 payments
  10. Amgen Inc. $282 15 payments
  11. Other $1,603 80 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,719 351 payments
  2. Travel and Lodging $970 2 payments
Products named General payments · program years 2021–2025
  1. WATCHMAN Access System $1,341 6 payments
  2. LEQVIO $444 27 payments
  3. ELIQUIS $412 31 payments
  4. ENTRESTO $358 24 payments
  5. Ozempic $342 20 payments
  6. RYBELSUS $342 20 payments
  7. XARELTO $339 30 payments
  8. NEXLETOL $305 13 payments
  9. FARXIGA $277 21 payments
  10. Repatha $268 14 payments
  11. Other $4,317 209 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

44

Median for Nurse Practitioner: 389

Drug cost

$17,595

Median for Nurse Practitioner: $21,885

Branded share of claims

36.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 16 $17,227
Metoprolol Succinate Generic 16 $312
Furosemide Generic 12 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $77
  • PFIZER INC. $41
$118 — —
INJECTAFER
  • Daiichi Sankyo Inc. $75
$75 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $65
$65 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $61
$61 — —
RYBELSUS
  • Novo Nordisk Inc $59
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

353 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record